Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products for specialized medical needs. Citius Pharmaceuticals, Inc. concentrates on areas such as oncology, anti-infectives, adjunct cancer care, prescription products, and stem cell therapy. Its current portfolio includes LYMPHIR, a targeted immunotherapy for cutaneous T-cell lymphoma, along with late-stage programs such as Mino-Lok for catheter-related bloodstream infections and Halo-Lido for hemorrhoid relief. The company also advances other product candidates aimed at hospital, oncology, and acute-care settings. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals, Inc. plays a role in bringing niche therapies and treatment options to patients and healthcare providers in markets with unmet clinical needs.
Website11 Commerce Drive
Cranford, NJ, 07016
United States
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City.
Detailed price information for Citius Pharmaceuticals Inc (CTXR-Q) from The Globe and Mail including charting and trades.
Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.
Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update.
Investors talking about CTXR also mention
What share of all stock conversation is about CTXR?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% 0 |
Of the messages about CTXR that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 0% -39.22 | 52.32% +3.66 | ||
| Bearish | — | — | 100% +39.22 | 47.68% -3.66 |
Of the messages about CTXR that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 80% | 87.31% | ||
| Analysts | — | — | 20% | 0.93% | ||
| Controversies | — | — | 0% | 0.93% | ||
| Earnings | — | — | 0% | 0% | ||
| Macro | — | — | 0% | 0% | ||
| Technical Analysis | — | — | 0% | 10.84% |
Of the messages about CTXR, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | 100% | 63.86% | ||
| Newcomers | — | — | 0% | 36.14% |